Showing 3481-3490 of 4062 results for "".
- CooperVision Myopia Control Research Receives Garland W. Clay Awardhttps://modernod.com/news/coopervision-myopia-control-research-receives-garland-w-clay-award/2480405/The American Academy of Optometry has awarded the 2021 Garland W. Clay Award to a team of researchers studying the effectiveness of CooperVision MiSight 1 day contact lenses in slowing the progression of myopia in children (aged 8-12 at the initiation of treatment).
- CooperVision Introduces MyDay Daily Disposable Multifocal Contact Lenses in UShttps://modernod.com/news/coopervision-introduces-myday-daily-disposable-multifocal-contact-lenses-in-us/2480403/At the 2021 American Academy of Optometry Meeting, CooperVision introduced MyDay daily disposable multifocal contact lenses, expanding its premium silicone hydrogel 1 day family in the United States. The new lenses are the first to feature the CooperVision
- Tarsus Pharmaceuticals Presents Data from Two Studies on the Prevalence and Impact of Demodex Blepharitishttps://modernod.com/news/tarsus-pharmaceuticals-presents-data-from-two-studies-on-the-prevalence-and-impact-of-demodex-blepharitis/2480402/Tarsus Pharmaceuticals presented data today from two pioneering studies on the prevalence and impact of Demodex blepharitis at the American Academy of Optometry (AAOpt) 2021 Annual Meeting in Boston. The Titan real-world prevalence study data revealed that Demodex blepharitis accounts for ov
- EyePoint Pharmaceuticals Appoints Jay S. Duker, MD, as Chief Operating Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-appoints-jay-s-duker-md-as-chief-operating-officer/2480387/EyePoint Pharmaceuticals announced the appointment of Jay S. Duker, MD, as Chief Operating Officer. Dr. Duker joined EyePoint as Chief Strategic Scientific Officer on a part-time basis in 2020, after having served as an independent member of EyePoint’s Board o
- FDA Clears Emergency Use of Comirnaty in Children Aged 5 to 11https://modernod.com/news/fda-clears-emergency-use-of-comirnaty-in-children-aged-5-to-11/2480386/The FDA on Friday authorized emergency use of Pfizer and BioNTech's Comirnaty for the prevention of COVID-19 to include children 5 through 11 years of age. The vaccine is administered as a two-dose primary series, 21 days apart, but at a lower 10-mcg dose than that used for individuals 12 yea
- EyeGate Pharmaceuticals Closes Acquisition of Bayon Therapeuticshttps://modernod.com/news/eyegate-pharmaceuticals-closes-acquisition-of-bayon-therapeutics/2480376/EyeGate Pharmaceuticals announced that it has completed the planned acquisition of Bayon Therapeutics and has appointed Eric J. Daniels, MD, MBA, as its Chief Development Officer, effective as of October 21, 2021. Dr. Daniels will drive ongoing development of EyeGate’
- Hanita Lenses Launches New Website as Part of 40th Anniversaryhttps://modernod.com/news/hanita-lenses-launches-new-website-as-part-of-40th-anniversary/2480365/Hanita Lenses has marked its 40th anniversary by launching a new website as part of its rebranding. Israel-based Hanita Lenses is a manufacturer and provider of intraocular lens solutions for cataract surgery.
- Prevent Blindness: Senate FY2022 Appropriations Bill Doubles Funding for the CDC’s Vision and Eye Health Programhttps://modernod.com/news/prevent-blindness-senate-fy2022-appropriations-bill-doubles-funding-for-the-cdcs-vision-and-eye-health-program/2480364/This week, the Senate Appropriations Committee released its proposed legislation to fund programs under the Department of Health and Human Services in Fiscal Year (FY) 2022. "As a result of continued Prevent Blindness advocacy efforts, the Senate Appropriations legislation includes
- MeiraGTx Announces the Presentation of Two Novel Inherited Retinal Disease (IRD) Programs and Riboswitch Gene Regulation Platformhttps://modernod.com/news/meiragtx-announces-the-presentation-of-two-novel-inherited-retinal-disease-ird-programs-and-riboswitch-gene-regulation-platform/2480359/MeiraGTx announced three poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 2021 Annual Congress. Two preclinical programs addressing inherited retinal diseases (IRDs) caused by mutations in KCNV2 and GUCY2D are presented with
- Clearside Biomedical Delivers Podium and Poster Presentations at ASRS Annual Meetinghttps://modernod.com/news/clearside-biomedical-delivers-podium-and-poster-presentations-at-asrs-annual-meeting/2480347/Clearside Biomedical announced that multiple presentations were given at the American Society of Retina Specialists (ASRS) Annual Meeting and at the OIS Retina Summit at ASRS, which took place October 7-12, 2021 in San Antonio, Texas. “The data pres